Core Insights - CeriBell, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $20.5 million, a 42% increase from $14.4 million in Q1 2024, driven by new account adoption and expansion within existing accounts [4][11] - The company is optimistic about continued growth in 2025, focusing on physician education and product development, including the introduction of a pediatric Clarity algorithm [3][8] Financial Performance - Total revenue for Q1 2025 was $20.5 million, up 42% from $14.4 million in Q1 2024, with product revenue at $15.6 million (41% increase) and subscription revenue at $4.9 million (45% increase) [4][15] - Gross profit for Q1 2025 was $18.0 million, with a gross margin of 88%, compared to $12.3 million and 86% in Q1 2024 [5][11] - Operating expenses increased by 55% to $32.2 million in Q1 2025, primarily due to investments in the commercial organization and increased headcount [6][11] - The net loss for Q1 2025 was $12.8 million, or $0.36 per share, compared to a net loss of $8.5 million, or $1.56 per share, in Q1 2024 [7][11] Future Outlook - CeriBell raised its revenue guidance for the full year 2025 to a range of $83 million to $87 million, indicating a growth of approximately 27% to 33% over the previous year [8] - The company ended Q1 2025 with 558 total active accounts and received FDA clearance for the expansion of its Clarity algorithm, marking a significant milestone [11][11] Company Overview - CeriBell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions through its innovative EEG platform [13]
Ceribell Reports First Quarter 2025 Financial Results